[Management of blood eosinophilia in an outpatient clinic for tropical diseases].

Presse Med

Unité de Parasitologie et Consultation de Maladies Tropicales, CHU de Bicêtre, AP-HP, Le Kremlin Bicêtre.

Published: January 2007

Objective: We assessed the frequency of parasitic diseases and the efficacy of presumptive treatment when no cause was found.

Materials And Methods: This prospective study took place in the Tropical Disease department of Bicêtre Hospital over a two-year period and included patients with eosinophil counts exceeding 500/mm(3).

Results: The study included 117 patients with blood eosinophilia. A parasitic infection was identified for 48 (41%), and appropriate treatment resulted in a return to normal eosinophil counts for all of them. No parasite was identified in 45 patients (38.5%), but parasitic disease was suspected on the basis of clinical or epidemiologic evidence. These patients received presumptive treatment with antiparasitic drugs (ivermectin, albendazole and praziquantel, alone or in combination). Of the 30 patients in this group not lost to follow-up, eosinophil counts returned to normal for 20. Finally, a cause other than parasitosis was suspected for 15 of the 117 patients (13%): 9 (7.5%) of them were lost to follow-up.

Discussion: Parasites remain the leading cause of blood eosinophilia. Because the sensitivity of additional testing for these parasites is low and these antiparasitic drugs are safe (except for patients with loiasis), presumptive treatment appears appropriate.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lpm.2006.10.011DOI Listing

Publication Analysis

Top Keywords

blood eosinophilia
12
presumptive treatment
12
eosinophil counts
12
117 patients
8
antiparasitic drugs
8
patients
7
[management blood
4
eosinophilia outpatient
4
outpatient clinic
4
clinic tropical
4

Similar Publications

Objective: To evaluate the characteristics of antifungal immunity in patients with bilateral chronic rhinosinusitis with nasal polyps.

Material And Methods: The study included 74 patients with bilateral chronic rhinosinusitis with nasal polyps and a control group consisting of 30 almost healthy individuals. All patients underwent surgery and were divided into two groups: Group I - with liquid secretion (=39), Group II - with thick secretion in the paranasal sinuses (=35).

View Article and Find Full Text PDF

Chronic hypereosinophilia, defined as persistent elevated blood levels of eosinophils ≥1,500/μL, is associated with tissue infiltration of eosinophils and consequent organ damage by eosinophil release of toxic mediators. The current therapies for chronic hypereosinophilia have limited success, require repetitive administration, and are associated with a variety of adverse effects. As a novel approach to treat chronic hypereosinophilia, we hypothesized that adeno-associated virus (AAV)-mediated delivery of an anti-human eosinophil antibody would provide one-time therapy that would mediate persistent suppression of blood eosinophil levels.

View Article and Find Full Text PDF

Beyond The Basics: Unveiling Superior Vena Cava Compression in Hodgkin's Lymphoma.

Cureus

November 2024

Internal Medicine/Pulmonary Critical Care, Appalachian Regional Healthcare, Harlan, USA.

Hodgkin's lymphoma (HL) is a malignancy of the lymphocytes in the lymph nodes and presents with non-specific systemic symptoms like fever, night sweats, and weight loss. While HL often involves the mediastinum, it rarely causes superior vena cava (SVC) syndrome, and eosinophilia is noted in approximately 15% of cases. Here, we report a unique presentation of HL in a 52-year-old male with a history of chronic pruritus, chronic kidney disease, and inactive hepatitis B.

View Article and Find Full Text PDF

There are many causes of peripheral blood eosinophilia (PBE), including allergic, infectious, rheumatic, and hematologic disorders. Solid tumor cancers, such as lung cancer, can also cause PBE, and although rare, being diagnosed with PBE in this way is associated with a worse prognosis than for lung cancer patients without PBE. Additionally, some cancer patients develop PBE when receiving treatment with immune checkpoint inhibitors (ICIs).

View Article and Find Full Text PDF

Background: Systemic lupus erythematosus is a multi-organ autoimmune disorder that is treated by immunosuppressive agents that weaken the immune defense against opportunistic pathogens and latent infections such as strongyloidiasis. Herein, we report the case of a 43-year-old woman known to have systemic lupus erythematosus who presented with gastrointestinal symptoms, edema, and bone pain 2 months after receiving immunosuppressive treatment.

Case Presentation: A 43-year-old Iranian female known to have systemic lupus erythematosus and antiphospholipid syndrome presented with abdominal pain, nausea, vomiting, and generalized edema.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!